Nathália Oliveira Acésio
Research Subjects
Nathália Oliveira Acésio has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Denise Crispim Tavares
Universidade de Franca
4 shared publications - Antonio Eduardo Miller Crotti
Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo
2 shared publications - Jackson Silva
Department of Chemistry, Faculty of Philosophy, Science and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-901, SP, Brazil
2 shared publications - Thaís A. S. Oliveira
Department of Chemistry, Faculty of Philosophy, Sciences, and Letters at Ribeirão Preto, University of São Paulo
2 shared publications - Ana Cláudia Oliveira Vilas Boas
University of Franca
1 shared publication - Ana Helena Januário
Universidade de Franca, Brasil
1 shared publication
Latest Publications
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Investigations of Oral Pathogens on Copper(II) Complexes with Thiosemicarbazone: Antimicrobial and Antibiofilm Activities in Addition to in vitro and in vivo Toxicity
Oral caries is a major global public health issue involving complex biofilm interactions and contributing to several systemic conditions. Metallic compounds have gained attention as antimicrobial agents due to their notable antibacterial activity. In this work, we investigated the anticariogenic potential of two copper(II) complexes containing Schiff base ligands, namely [CuCl(atc-Me)] (1, atc-Me = 2-acetylpyridine-N(4)-methyl-thiosemicarbazone) and [{Cu(μ‑atc‑Me)}2μ-SO4] (2). Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), minimum biofilm inhibitory concentration (MBIC50), and synergistic activity with chlorhexidine were evaluated. The in vivo toxicity of the complexes was further assessed using Caenorhabditis elegans. MBC values indicated a bactericidal effect for both complexes. Synergistic activity with chlorhexidine was observed against Streptococcus mutans and Enterococcus faecalis strains. Cytotoxic evaluation in human fibroblast cultures revealed that complexes 1 and 2 showed half maximal inhibitory concentration (IC50) values of 2.9 and 4.9 µg mL–1, respectively. Toxicity assays in C. elegans showed lethal concentration (LC50) values approximately three times higher than the MIC values for complexes 1 and 2. Molecular docking analyses revealed favorable binding energy values between the copper complexes and bacterial proteins. Overall, this investigation suggests an alternative approach for anticariogenic treatment, highlighting significant antibiofilm activity combined with low toxicity.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Investigations of Oral Pathogens on Copper(II) Complexes with Thiosemicarbazone: Antimicrobial and Antibiofilm Activities in Addition to in vitro and in vivo Toxicity
Oral caries is a major global public health issue involving complex biofilm interactions and contributing to several systemic conditions. Metallic compounds have gained attention as antimicrobial agents due to their notable antibacterial activity. In this work, we investigated the anticariogenic potential of two copper(II) complexes containing Schiff base ligands, namely [CuCl(atc-Me)] (1, atc-Me = 2-acetylpyridine-N(4)-methyl-thiosemicarbazone) and [{Cu(μ‑atc‑Me)}2μ-SO4] (2). Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), minimum biofilm inhibitory concentration (MBIC50), and synergistic activity with chlorhexidine were evaluated. The in vivo toxicity of the complexes was further assessed using Caenorhabditis elegans. MBC values indicated a bactericidal effect for both complexes. Synergistic activity with chlorhexidine was observed against Streptococcus mutans and Enterococcus faecalis strains. Cytotoxic evaluation in human fibroblast cultures revealed that complexes 1 and 2 showed half maximal inhibitory concentration (IC50) values of 2.9 and 4.9 µg mL–1, respectively. Toxicity assays in C. elegans showed lethal concentration (LC50) values approximately three times higher than the MIC values for complexes 1 and 2. Molecular docking analyses revealed favorable binding energy values between the copper complexes and bacterial proteins. Overall, this investigation suggests an alternative approach for anticariogenic treatment, highlighting significant antibiofilm activity combined with low toxicity.
- 27 March 2025
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 88 (16) , 656-666
Evaluation of acute oral toxicity to rats, genotoxicity to mice, and toxicity to non-vertebrate animals attributed to Vochysia divergens stem bark extract exposure
Vochysia divergens (Vochysiaceae), present in the flooded fields of Pantanal in the state of Mato Grosso, Brazil, is traditionally used to treat infections. However, studies on the toxicological safety of using the stem bark of this vegetable are lacking. This study aimed to investigate acute oral toxicity using rats, genotoxicity utilizing mice, and toxicity to non-vertebrate animals, the insect Galleria mellonella and the nematode Caenorhabditis elegans following exposure to V. divergens stem bark ethanolic extract (VDSE). In addition, phytochemical analyses were performed using HPLC-PDA, and the total triterpene content in VDSE was determined. At 2000 mg/kg, VDSE did not induce acute toxicity. In mice treated with different VDSE doses (500, 1000, or 2000 mg/kg), no chromosomal damages or altered ratios of polychromatic erythrocytes to total erythrocytes were noted. VDSE also did not induce toxicity to G. mellonela and C. elegans as evidenced by 100% survival. The extract contained a total triterpene content of 780 mg g (39%). Since VDSE exerts a beneficial role in treating infections, it is essential to determine the risks associated with consuming these plant species to establish safety. Consequently, the present results expand knowledge regarding VDSE chemical quality control and safety.
- 27 March 2025
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 88 (16) , 656-666
Evaluation of acute oral toxicity to rats, genotoxicity to mice, and toxicity to non-vertebrate animals attributed to Vochysia divergens stem bark extract exposure
Vochysia divergens (Vochysiaceae), present in the flooded fields of Pantanal in the state of Mato Grosso, Brazil, is traditionally used to treat infections. However, studies on the toxicological safety of using the stem bark of this vegetable are lacking. This study aimed to investigate acute oral toxicity using rats, genotoxicity utilizing mice, and toxicity to non-vertebrate animals, the insect Galleria mellonella and the nematode Caenorhabditis elegans following exposure to V. divergens stem bark ethanolic extract (VDSE). In addition, phytochemical analyses were performed using HPLC-PDA, and the total triterpene content in VDSE was determined. At 2000 mg/kg, VDSE did not induce acute toxicity. In mice treated with different VDSE doses (500, 1000, or 2000 mg/kg), no chromosomal damages or altered ratios of polychromatic erythrocytes to total erythrocytes were noted. VDSE also did not induce toxicity to G. mellonela and C. elegans as evidenced by 100% survival. The extract contained a total triterpene content of 780 mg g (39%). Since VDSE exerts a beneficial role in treating infections, it is essential to determine the risks associated with consuming these plant species to establish safety. Consequently, the present results expand knowledge regarding VDSE chemical quality control and safety.
- Open Access
- 27 August 2024
- Published by MDPI AG in Future Pharmacology
- Vol. 4 (3) , 564-573
Anticancer Activity of 4-Aryl-1,4-Dihydropyridines
We have synthesized 22 symmetric and asymmetric 4-aryl-1,4-dihydropyridines (1,4-DHPs) by a “green” microwave-assisted one-pot multicomponent Hantzsch reaction and evaluated their cytotoxicity to three human cancer cell lines regarding U-251MG (human glioblastoma), HeLa 229 (human cervical adenocarcinoma), and MCF-7 (human breast carcinoma). None of the 1,4-DHPs were cytotoxic to U-251MG cells. Most of the 1,4-DHPs did not affect HeLa 229 or MCF-7 cell viability. On the other hand, symmetric 1,4-DHPs 18 (diethyl 4-(4-benzyloxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate), 19 (diethyl 4-(4-bromophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate), and 20 (diethyl 4-(3-fluorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate) reduced the HeLa (IC50 = 3.6, 2.3, and 4.1 µM, respectively) and MCF-7 (IC50 = 5.2, 5.7, and 11.9 µM, respectively) cell viability. These 1,4-DHPs were more cytotoxic to the HeLa and MCF-7 cells than to the GM07492 (normal human fibroblast) cells, as evidenced by their selectivity indexes. Therefore,1,4-DHPs 18, 19, and 20 may serve as novel lead compounds to discover other 1,4-DHP derivatives with improved anticancer potency and selectivity.
- 27 August 2024
- Published by MDPI AG in Future Pharmacology
- Vol. 4 (3) , 564-573
Open AccessAnticancer Activity of 4-Aryl-1,4-Dihydropyridines
We have synthesized 22 symmetric and asymmetric 4-aryl-1,4-dihydropyridines (1,4-DHPs) by a “green” microwave-assisted one-pot multicomponent Hantzsch reaction and evaluated their cytotoxicity to three human cancer cell lines regarding U-251MG (human glioblastoma), HeLa 229 (human cervical adenocarcinoma), and MCF-7 (human breast carcinoma). None of the 1,4-DHPs were cytotoxic to U-251MG cells. Most of the 1,4-DHPs did not affect HeLa 229 or MCF-7 cell viability. On the other hand, symmetric 1,4-DHPs 18 (diethyl 4-(4-benzyloxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate), 19 (diethyl 4-(4-bromophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate), and 20 (diethyl 4-(3-fluorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate) reduced the HeLa (IC50 = 3.6, 2.3, and 4.1 µM, respectively) and MCF-7 (IC50 = 5.2, 5.7, and 11.9 µM, respectively) cell viability. These 1,4-DHPs were more cytotoxic to the HeLa and MCF-7 cells than to the GM07492 (normal human fibroblast) cells, as evidenced by their selectivity indexes. Therefore,1,4-DHPs 18, 19, and 20 may serve as novel lead compounds to discover other 1,4-DHP derivatives with improved anticancer potency and selectivity.
- Open Access
- 10 July 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Anticancer activity of 4-aryl-1,4-dihydropyridines
We have synthesized 22 symmetric and asymmetric 4-aryl-1,4-dihydropyridines (1,4-DHPs) by a “green” microwave-assisted one-pot multicomponent Hantzsch reaction and evaluated their cy-totoxicity to three human cancer cell lines viz. U-251MG (human glioblastoma), HeLa 229 (human cervical adenocarcinoma), and MCF-7 (human breast carcinoma). None of the 1,4-DHPs were cytotoxic to U-251MG cells. Most of the 1,4-DHPs did not affect HeLa 229 or MCF-7 cell viability. On the other hand, the symmetric 1,4-DHPs 18 ((±)-diethyl 4-(4-benzyloxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate), 19 ((±)-diethyl 4-(4-bromophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate), and 20 ((±)-diethyl 4-(3-fluor-4-hydroxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate) reduced HeLa (IC50 = 3.6, 2.3, and 4.1 µM, respectively) and MCF-7 (IC50 = 5.2, 5.7, and 11.9 µM, respectively) cell viability. These 1,4-DHPs were more cytotoxic to HeLa and MCF-7 cells than to GM07492 (normal human fibroblast) cells, as evidenced by their selectivity indexes. Therefore,1,4-DHPs 18, 19, and 20 may serve as novel lead compounds to discover other 1,4-DHP derivatives with improved anti-cancer potency and selectivity.
- 10 July 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAnticancer activity of 4-aryl-1,4-dihydropyridines
We have synthesized 22 symmetric and asymmetric 4-aryl-1,4-dihydropyridines (1,4-DHPs) by a “green” microwave-assisted one-pot multicomponent Hantzsch reaction and evaluated their cy-totoxicity to three human cancer cell lines viz. U-251MG (human glioblastoma), HeLa 229 (human cervical adenocarcinoma), and MCF-7 (human breast carcinoma). None of the 1,4-DHPs were cytotoxic to U-251MG cells. Most of the 1,4-DHPs did not affect HeLa 229 or MCF-7 cell viability. On the other hand, the symmetric 1,4-DHPs 18 ((±)-diethyl 4-(4-benzyloxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate), 19 ((±)-diethyl 4-(4-bromophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate), and 20 ((±)-diethyl 4-(3-fluor-4-hydroxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate) reduced HeLa (IC50 = 3.6, 2.3, and 4.1 µM, respectively) and MCF-7 (IC50 = 5.2, 5.7, and 11.9 µM, respectively) cell viability. These 1,4-DHPs were more cytotoxic to HeLa and MCF-7 cells than to GM07492 (normal human fibroblast) cells, as evidenced by their selectivity indexes. Therefore,1,4-DHPs 18, 19, and 20 may serve as novel lead compounds to discover other 1,4-DHP derivatives with improved anti-cancer potency and selectivity.